Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Affiliations

¹ Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan. nbryamam@ncc.go.jp.
² Department of Thoracic Oncology, National Cancer Centre Hospital East, Kashiwa, Chiba, Japan.
³ Thoracic Oncology Centre, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
⁴ Oncology Medicine, National Hospital Organization, Yamaguchi-Ube Medical Centre, Ube, Yamaguchi, Japan.
⁵ Department of Thoracic Oncology, Aichi Cancer Centre Hospital, Nagoya, Aichi, Japan.
⁶ Department of Respiratory Medicine, Miyagi Cancer Centre, Natori, Miyagi, Japan.
⁷ Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo, Japan.
⁸ Department of Thoracic Oncology, National Hospital Organization, Shikoku Cancer Centre, Matsuyama, Ehime, Japan.
⁹ Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
¹⁰ Department of Thoracic Oncology, National Kyushu Cancer Centre, Fukuoka, Fukuoka, Japan.
¹¹ Clinical Research Planning Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan.
¹² Thoracic Center, St Luke's International Hospital, Chuo-ku, Tokyo, Japan.

Published Erratum

Noboru Yamamoto et al. Int J Clin Oncol. 2017 Feb.

. 2017 Feb;22(1):79.

doi: 10.1007/s10147-016-1052-3.

¹ Department of Thoracic Oncology, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan. nbryamam@ncc.go.jp.
² Department of Thoracic Oncology, National Cancer Centre Hospital East, Kashiwa, Chiba, Japan.
³ Thoracic Oncology Centre, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
⁴ Oncology Medicine, National Hospital Organization, Yamaguchi-Ube Medical Centre, Ube, Yamaguchi, Japan.
⁵ Department of Thoracic Oncology, Aichi Cancer Centre Hospital, Nagoya, Aichi, Japan.
⁶ Department of Respiratory Medicine, Miyagi Cancer Centre, Natori, Miyagi, Japan.
⁷ Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo, Japan.
⁸ Department of Thoracic Oncology, National Hospital Organization, Shikoku Cancer Centre, Matsuyama, Ehime, Japan.
⁹ Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
¹⁰ Department of Thoracic Oncology, National Kyushu Cancer Centre, Fukuoka, Fukuoka, Japan.
¹¹ Clinical Research Planning Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan.
¹² Thoracic Center, St Luke's International Hospital, Chuo-ku, Tokyo, Japan.

No abstract available

Erratum for

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T. Yamamoto N, et al. Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22. Int J Clin Oncol. 2017. PMID: 27659294 Free PMC article. Clinical Trial.